Evolving Guideline Recommendations for IgA Nephropathy Treatment and Management: What You Need to Know - CME

CME

Title: Evolving Guideline Recommendations for IgA Nephropathy Treatment and Management: What You Need to Know

Description: The goal of this activity is for learners to be better able to understand how the guideline recommendations on immunoglobulin A nephropathy (IgAN) management have evolved and why they have changed, and to better appreciate the implications for clinical practice.

Target Audience: This educational activity is intended for an audience of nephrologists, primary care physicians, and urologists in the United States.

Learning Objectives

Have increased knowledge regarding the
- Newest guideline recommendations for managing patients with IgAN
Demonstrate greater confidence in their ability to
- Incorporate the newest guideline recommendations for IgAN management into clinical practice

Disclosures and Disclaimers: Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	0.25 Credits	ACCME- Accreditation Council for Continuing Medical Education